Kyntra Bio, Inc. (KYNB)
7.20
+0.12
(+1.77%)
USD |
NASDAQ |
Sep 21, 16:00
7.34
+0.14
(+1.94%)
After-Hours: 07:29
Kyntra Bio EPS Diluted (TTM) : 32.31 for June 30, 2026
EPS Diluted (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 32.31 |
| March 31, 2026 | 27.47 |
| December 31, 2025 | 31.27 |
| September 30, 2025 | 39.34 |
| June 30, 2025 | -1.625 |
| March 31, 2025 | -3.637 |
| December 31, 2024 | -12.00 |
| September 30, 2024 | -30.73 |
| June 30, 2024 | -27.13 |
| March 31, 2024 | -24.14 |
| December 31, 2023 | -16.63 |
| September 30, 2023 | -3.059 |
| June 30, 2023 | -3.388 |
| March 31, 2023 | -3.268 |
| December 31, 2022 | -3.137 |
| September 30, 2022 | -3.879 |
| June 30, 2022 | -2.365 |
| March 31, 2022 | -3.040 |
| December 31, 2021 | -3.143 |
| September 30, 2021 | -17.78 |
| June 30, 2021 | -17.96 |
| March 31, 2021 | -17.46 |
| December 31, 2020 | -17.57 |
| September 30, 2020 | -2.613 |
| June 30, 2020 | -3.533 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.315 |
| December 31, 2019 | -0.9568 |
| September 30, 2019 | 0.3961 |
| June 30, 2019 | 0.4607 |
| March 31, 2019 | -1.084 |
| December 31, 2018 | -1.053 |
| September 30, 2018 | -11.60 |
| June 30, 2018 | -19.15 |
| March 31, 2018 | -30.33 |
| December 31, 2017 | -41.78 |
| September 30, 2017 | -32.00 |
| June 30, 2017 | -24.32 |
| March 31, 2017 | -12.51 |
| December 31, 2016 | -1.014 |
| September 30, 2016 | -1.31 |
| June 30, 2016 | -1.67 |
| March 31, 2016 | -1.19 |
| December 31, 2015 | -1.52 |
| September 30, 2015 | -2.14 |
| June 30, 2015 | -2.828 |
| March 31, 2015 | -3.198 |
| December 31, 2014 | -2.704 |
| September 30, 2014 | -1.418 |
| June 30, 2014 | -0.3106 |
| March 31, 2014 | -0.7705 |
EPS Diluted (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (TTM) Benchmarks
| Vericel Corp. | 0.4623 |
| Capricor Therapeutics, Inc. | -2.449 |
| ARS Pharmaceuticals, Inc. | -2.173 |
| ACADIA Pharmaceuticals, Inc. | 2.220 |
| Alnylam Pharmaceuticals, Inc. | 5.923 |